openPR Logo
Press release

Sarcopenia Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

01-30-2023 10:28 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Sarcopenia Pipeline Appears Robust With 12+ Key Pharma

DelveInsight's, "Sarcopenia Pipeline Insight, 2023," report provides comprehensive insights about 12+ companies and 14+ pipeline drugs in Sarcopenia pipeline landscape. It covers the Sarcopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcopenia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Sarcopenia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Sarcopenia Pipeline Report

• Sarcopenia Pipeline report offers a comprehensive analysis of 12+ companies and 14+ therapies.

• The leading Sarcopenia Companies includes Lipocine Inc., MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Oncocross Therapeutics, OPKO health, NMD Pharma, Rejuvenate Biomed, Immunoforge, Rubedo Life Sciences, Faraday Pharmaceuticals, Actimed Therapeutics, Pephexia Therapeutics, and others.

• Promising Sarcopenia Pipeline Therapies includes REGN1033 (SAR391786), bimagrumab, Astaxanthin formulation, bimagrumab, LPCN 1148, and others.

• The Sarcopenia companies and academics are working to assess challenges and seek opportunities that could influence Sarcopenia R&D. The Sarcopenia pipeline therapies under development are focused on novel approaches to treat/improve Sarcopenia.

Explore more information on the latest breakthroughs in the Sarcopenia treatment landscape of the report and Sarcopenia Pipeline Outlook @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sarcopenia Overview
Sarcopenia is a musculoskeletal disease in which muscle mass, strength, and performance are significantly compromised with age. Sarcopenia most commonly affects elderly and sedentary populations and patients who have comorbidities that affect the musculoskeletal system or impair physical activity. The diagnosis of sarcopenia encompasses decreased levels of the following 3 traits: muscle strength, muscle quantity or quality, and physical performance. Causes of sarcopenia are generally attributable to the natural processes of aging, which are not entirely understood and are multifaceted. Risk factors for sarcopenia include age, gender and level of physical activity. The main treatment path for sarcopenia is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to people with sarcopenia.

Recent Development Activities in the Sarcopenia Treatment Landscape
In January 2022, MyMD Pharma announced that he U.S. Patent and Trademark Office (USPTO) awarded to the company U.S. Patent 11,219,620 B2, titled "Method of Treating Sarcopenia." The patent was issued on January 11, 2022. Currently it is being evaluated in Phase II clinical studies to treat patients with Sarcopenia.

Request a sample and discover the recent advances in Sarcopenia Pipeline Therapies, visit Sarcopenia Treatment Landscape @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sarcopenia Pipeline Therapeutics Assessment
There are approx. 12+ key companies which are developing the therapies for Sarcopenia. The Sarcopenia companies which have their Sarcopenia drug candidates in the most advanced stage, i.e. phase III include, Biophytis.

Sarcopenia Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Get to know more information about the Sarcopenia Emerging Drugs and Sarcopenia Companies of the report @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Sarcopenia Pipeline Report
• Coverage- Global
• Companies- Lipocine Inc., MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Oncocross Therapeutics, OPKO health, NMD Pharma, Rejuvenate Biomed, Immunoforge, Rubedo Life Sciences, Faraday Pharmaceuticals, Actimed Therapeutics, Pephexia Therapeutics, and others.
• Pipeline Therapies- REGN1033 (SAR391786), bimagrumab, Astaxanthin formulation, bimagrumab, LPCN 1148, and others.
• Sarcopenia Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Sarcopenia Market Drivers and Sarcopenia Market Barriers, click here Sarcopenia Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Sarcopenia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sarcopenia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Sarconeos (BIO101): Biophytis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MYMD-1: MyMD Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PF-1801: PhaseBio Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Sarcopenia Key Companies
21. Sarcopenia Key Products
22. Sarcopenia- Unmet Needs
23. Sarcopenia- Market Drivers and Barriers
24. Sarcopenia- Future Perspectives and Conclusion
25. Sarcopenia Analyst Views
26. Sarcopenia Key Companies
27. Appendix

Got Queries? Find out the related information on Sarcopenia Mergers and acquisitions, Sarcopenia Licensing Activities, and Click here for Sarcopenia Emerging Drugs, and Recent Trends @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Trending Market Research Reports in 2023 By DelveInsight

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Oncolytic virus cancer therapy pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Persistent Corneal Epithelial Defects Market- https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

Technical Due Diligence Firms | Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services

Shingles Market- https://www.delveinsight.com/report-store/shingles-market

Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome Market- https://www.delveinsight.com/report-store/hand-foot-syndrome-market

Ptosis Market- https://www.delveinsight.com/report-store/ptosis-market

Uncomplicated Urinary Tract Infection Market- https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market

Otitis Media Market- https://www.delveinsight.com/report-store/otitis-media-market

Pelizaeus-Merzbacher Disease Market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market

Transverse Myelitis Market- https://www.delveinsight.com/report-store/transverse-myelitis-market

PCSK9 Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-market

Cough in IPF Market- https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market

Diabetes Insipidus Market- https://www.delveinsight.com/report-store/diabetes-insipidus-market

Advanced Liver Cancer Market- https://www.delveinsight.com/report-store/advanced-liver-cancer-market

Chagas Disease Market- https://www.delveinsight.com/report-store/chagas-disease-market

Familial Adenomatous Polyposis Market- https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market

Metastatic Pancreatic Cancer Market- https://www.delveinsight.com/report-store/metastatic-pancreatic-cancer-mpc-market

Trichotillomania Market- https://www.delveinsight.com/report-store/trichotillomania-ttm-market

Temporomandibular Disorders Market- https://www.delveinsight.com/report-store/temporomandibular-disorders-market

Testicular Neoplasm Market- https://www.delveinsight.com/report-store/testicular-neoplasm-market

Joint Reconstruction Devices Market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market

Rhinosinusitis Market- https://www.delveinsight.com/report-store/rhinosinusitis-market

Atrial Flutter Market- https://www.delveinsight.com/report-store/atrial-flutter-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sarcopenia Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here

News-ID: 2903849 • Views:

More Releases from DelveInsight Business Research

DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) Across 15 Countries
DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous …
DelveInsight, a global leader in healthcare research and analytics, announces the release of its in-depth Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment, providing unparalleled insights into the prevalence of cSCC among solid organ transplant recipients across 15 countries, including the United States, key European nations, and select countries in the Asia-Pacific (APAC) region. The newly released assessment delivers country-specific epidemiological insights aimed at guiding strategic decision-making for pharmaceutical companies, healthcare providers,
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (PFO) Device Landscape Analysis Empowers Strategic Market Entry in the EU
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (P …
DelveInsight's Market Size & Forecast Assessment Provides Data-Driven Insights for Patient-Centric Market Expansion Strategies DelveInsight, a leading healthcare market research and consulting firm, has released an in-depth case study highlighting its latest assessment of the Patent Foramen Ovale (PFO) Device Market across the European Union. This strategic market intelligence report provides a holistic understanding of the patient population, device market size, competitor landscape, and reimbursement scenario, equipping medical device companies with
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for Robust Growth at 6.35% CAGR through 2032, States DelveInsight
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for …
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set for strong expansion, projected to grow at a CAGR of 6.35% from 2025 to 2032, according to recent industry findings. This growth is primarily fueled by the increasing global prevalence of COPD, escalating exposure to tobacco smoke and air pollution, expanding screening programs, and the rapid development of next-generation respiratory devices such as portable nebulizers and smart inhalers. The global
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market. The CD40 Pipeline report embraces in-depth commercial and

All 5 Releases


More Releases for Sarcopenia

Sarcopenia Market Size, Share & Growth Analysis 2034
Sarcopenia Market Overview Sarcopenia is a condition characterized by the progressive loss of muscle mass, strength, and function, primarily affecting the elderly. This decline leads to increased frailty, higher risk of falls, and diminished quality of life. The rising global geriatric population has heightened the prevalence of sarcopenia, making it a significant public health concern. Consequently, there is a growing demand for effective treatments and interventions to manage and mitigate the
Sarcopenia Treatment Market Future Prediction Report By 2030
Sarcopenia Treatment Market business research report assesses the current as well as upcoming performance of the market, also brand-new trends in the market. It provides product overview and highlights of product and application segments of the market including price, revenue, sales, sales growth rate, and market share by product. The market statistics within the report is displayed in a statistical format to offer a better understanding upon the market dynamics.
Sarcopenia Treatment Market Report 2024 - Sarcopenia Treatment Market Size And G …
"The Business Research Company recently released a comprehensive report on the Global Sarcopenia Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The sarcopenia treatment market
Sarcopenia Pipeline Insights Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Sarcopenia Pipeline constitutes 8+ key companies continuously working towards developing 10+ Sarcopenia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. In the Sarcopenia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product
Global Sarcopenia Therapeutic Market Research Report 2023
The global Sarcopenia Therapeutic market was valued at US$ 2867.6 million in 2022 and is anticipated to reach US$ 3484.4 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029. view full report https://reports.valuates.com/market-reports/QYRE-Auto-13K14453/global-sarcopenia-therapeutic Sarcopenia Therapeutic Market Sarcopenia is a syndrome caused by continuous loss of skeletal muscle mass, strength, and function. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. China is the largest consumption region of
Sarcopenia - Drug Pipeline Landscape, 2022
Sarcopenia is a condition characterized by the loss of muscle mass and strength. It can occur due to a variety of reasons, including aging, inactivity, and certain chronic diseases. Aging is the most common cause of sarcopenia. As people age, they tend to become less active and lose muscle mass. This process is known as age-related muscle loss or sarcopenia with aging. Inactivity can also lead to sarcopenia. People who are not